A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Clozapine has markedly superior clinical properties compared to other antipsychotic drugs but the side effects of agranulocytosis, weight gain and diabetes limit its use. The reason why clozapine is more effective is not well understood. We studied messenger RNA (mRNA) gene expression in the mouse brain to identify pathways changed by clozapine compared to those changed by haloperidol so that we could identify which changes were specific to clozapine. Data interpretation was performed using an over-representation analysis (ORA) of gene ontology (GO), pathways and gene-by-gene differences. Clozapine significantly changed gene expression in pathways related to neuronal growth and differentiation to a greater extent than haloperidol; including the microtubule-associated protein kinase (MAPK) signalling and GO terms related to axonogenesis and neuroblast proliferation. Several genes implicated genetically or functionally in schizophrenia such as frizzled homolog 3 (FZD3), U2AF homology motif kinase 1 (UHMK1), pericentriolar material 1 (PCM1) and brain-derived neurotrophic factor (BDNF) were changed by clozapine but not by haloperidol. Furthermore, when compared to untreated controls clozapine specifically regulated transcripts related to the glutamate system, microtubule function, presynaptic proteins and pathways associated with synaptic transmission such as clathrin cage assembly. Compared to untreated controls haloperidol modulated expression of neurotoxic and apoptotic responses such as NF-kappa B and caspase pathways, whilst clozapine did not. Pathways involving lipid and carbohydrate metabolism and appetite regulation were also more affected by clozapine than by haloperidol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“…are directly responsible for the clozapinerelated metabolic profile, it is of note that several lines of evidence support the orexigenic role of insulin, leptin, neuropeptide signalling and cannabinoid signalling in clozapine-related weight gain and metabolic anomalies (Allison et al., 1999).”
BackgroundCommon variants conferring risk of schizophrenia
†Genetic Risk and Outcome in Psychosis (GROUP), Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietiläinen, O. P. H., Mors, O., et al. (2009) · Nature · doi:10.1038/nature08186 · Cited by 1,677 · cited 2×
“, 2007, 2008 and PCM1 is associated with schizophrenia in 10 samples with over 61 single nucleotide polymorphisms (SNP) showing association (Datta et al., 2010; Gurling et al., 2006; ISC, 2009; Moens et al., 2010; Need et al., 2009; Stefansson et al., 2009; Sullivan et al., 2008; TabaresSeisdedos and Rubenstein, 2009).”
BackgroundDisruption of two novel genes by a translocation co-segregating with schizophrenia
Millar, J. K. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.9.1415 · Cited by 1,254 · cited 1×
“…et al., 2010), Disrupted-In-Schizophrenia 1 (DISC1) (Brandon et al., 2004; Hennah et al., 2003, 2009; Hodgkinson et al., 2004; James et al., 2004; Millar et al., 2000, 2003, 2004; Sawamura et al., 2005; Schurov et al., 2004), Fasciculation and elongation protein zeta-1 (FEZ1) (Miyoshi et al.,…”
Tabarés-Seisdedos, R., & Rubenstein, J. L. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.2 · Cited by 244 · cited 1×
“FZD3 has been genetically implicated in schizophrenia several times (Tabares-Seisdedos and Rubenstein, 2009; Zhang et al., 2004).”
BackgroundTowards understanding the schizophrenia code: an expanded convergent functional genomics approach
Le‐Niculescu, H., Balaraman, Y., Patel, S., Tan, J., Sidhu, K., Jerome, R. E., Edenberg, H. J., Kuczenski, R., Geyer, M. A., Nurnberger, J. I., et al. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30481 · Cited by 137
Halim, N. D., Weickert, C. S., McClintock, B. W., Hyde, T. M., Weinberger, D. R., Kleinman, J. E., & Lipska, B. K. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001319 · Cited by 124 · cited 1×
“Several studies have reported reductions in the levels and activity of presynaptic proteins in the brains of subjects with schizophrenia (Castillo et al., 2010; Halim et al., 2003).”
BackgroundMelkersson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0614 · Cited by 98 · cited 2×
“, 2004; Tandon, 2002) and hyperprolactinaemia (Hamner, 2002; Melkersson, 2005; Volavka et al., 2004; Wudarsky et al., 1999).”
BackgroundEffect of Y1 receptor deficiency on motor activity, exploration, and anxiety
Karl, T., Burne, T. H. J., & Herzog, H. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.08.019 · Cited by 95
Katsu, T., Ujike, H., Nakano, T., Tanaka, Y., Nomura, A., Nakata, K., Takaki, M., Sakai, A., Uchida, N., Imamura, T., et al. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.017 · Cited by 80
Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat
Arguello, P. A., & Jentsch, J. D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1953-0 · Cited by 49
Cited by
Gene expression elucidates functional impact of polygenic risk for schizophrenia
Fromer, M., Roussos, P., Sieberts, S. K., Johnson, J. S., Kavanagh, D. H., Perumal, T. M., Ruderfer, D. M., Oh, E. C., Topol, A., Shah, H. R., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4399 · Cited by 1,091
de Bartolomeis, A., Buonaguro, E. F., Latte, G., Rossi, R., Marmo, F., Iasevoli, F., & Tomasetti, C. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00240 · Cited by 44
“…or Haloperidol ↓ Hippocampus Lipska et al., 2001 Chronic Aripiprazole ↓ Hippocampus Luoni et al., 2014a Chronic Clozapine ↑ Whole rat brain Kim et al., 2012; Rizig et al., 2012 Chronic Haloperidol or high-dose Risperidone ↓ Hippocampus Chlan-Fourney et al., 2002; Parikh et al.,…”
BackgroundMechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry
Bortolasci, C. C., Spolding, B., Callaly, E., Martin, S., Panizzutti, B., Kidnapillai, S., Connor, T., Hasebe, K., Mohebbi, M., Dean, O. M., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy014 · Cited by 25
“Most useful psychotropic medications produce maximal responses after several weeks, and this observation indicates that chronic adaptive molecular changes are crucial components of successful treatment rather than simple immediate receptor binding effects (Rizig et al., 2012).”
Backgroundde Bartolomeis, A., Iasevoli, F., Tomasetti, C., & Buonaguro, E. F. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8962-8 · Cited by 21
Metadata
- Authors
- Rizig, M. A., McQuillin, A., Ng, A., Robinson, M., Harrison, A., Zvelebil, M., Hunt, S. P., & Gurling, H. M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-07-05
- Volume
- 26
- Issue
- 9
- Pages
- 1218-1230
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2023038496
- Cited by
- 39
- References
- 10
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia. https://app.cochat.ai/papers/10.1177/0269881112450780
- The paper
- Rizig, M. A., McQuillin, A., Ng, A., Robinson, M., Harrison, A., Zvelebil, M., Hunt, S. P., & Gurling, H. M. (2012). A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia. Journal of Psychopharmacology. https://doi.org/10.1177/0269881112450780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.